Gabelli Funds LLC lifted its position in Baxter International Inc. (NYSE:BAX – Free Report) by 7.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,200 shares of the medical instruments supplier’s stock after buying an additional 20,000 shares during the quarter. Gabelli Funds LLC owned about 0.06% of Baxter International worth $10,242,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also modified their holdings of the company. Innealta Capital LLC bought a new position in Baxter International in the 2nd quarter worth $27,000. LRI Investments LLC bought a new position in shares of Baxter International in the first quarter worth about $39,000. United Community Bank bought a new position in shares of Baxter International in the fourth quarter worth about $43,000. Versant Capital Management Inc lifted its position in shares of Baxter International by 974.2% during the 2nd quarter. Versant Capital Management Inc now owns 1,332 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 1,208 shares during the last quarter. Finally, Trust Co. of Vermont boosted its stake in Baxter International by 31.0% during the 4th quarter. Trust Co. of Vermont now owns 1,870 shares of the medical instruments supplier’s stock valued at $72,000 after purchasing an additional 443 shares during the period. 90.19% of the stock is currently owned by institutional investors and hedge funds.
Baxter International Stock Performance
NYSE BAX opened at $39.00 on Tuesday. Baxter International Inc. has a twelve month low of $31.01 and a twelve month high of $44.01. The company has a quick ratio of 0.91, a current ratio of 1.40 and a debt-to-equity ratio of 1.35. The stock has a market cap of $19.87 billion, a P/E ratio of 7.50, a PEG ratio of 1.33 and a beta of 0.59. The company’s 50-day simple moving average is $37.12 and its 200 day simple moving average is $37.30.
Baxter International Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Friday, August 30th will be issued a dividend of $0.29 per share. The ex-dividend date is Friday, August 30th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 2.97%. Baxter International’s payout ratio is presently 22.31%.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. JPMorgan Chase & Co. dropped their price target on Baxter International from $44.00 to $42.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Evercore ISI cut their target price on shares of Baxter International from $46.00 to $45.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Wells Fargo & Company decreased their price target on shares of Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 7th. The Goldman Sachs Group upped their price objective on shares of Baxter International from $36.00 to $40.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. Finally, Morgan Stanley downgraded Baxter International from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $39.00 to $30.00 in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $41.73.
Read Our Latest Report on Baxter International
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Featured Articles
- Five stocks we like better than Baxter International
- Consumer Staples Stocks, Explained
- The Average 401k Balance by Age Explained
- What Are Dividend Champions? How to Invest in the Champions
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.